Originally published In Press as doi:10.1074/mcp.M900180-MCP200 on August 11, 2009.
Molecular & Cellular Proteomics 8:2582-2594, 2009.
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
Research
Glucose-regulated Protein 78 Is an Intracellular Antiviral Factor against Hepatitis B Virus*,
Yan Ma ,
Jun Yu ,¶,
Henry L. Y. Chan ,
Yang-chao Chen ,
Hua Wang ,
Ying Chen ,
Chu-yan Chan ,
Minnie Y. Y. Go ,
Sau-na Tsai||,
Sai-ming Ngai||,
Ka-fai To¶,**,
Joanna H. M. Tong¶,**,
Qing-Yu He ,
Joseph J. Y. Sung ,¶,
Hsiang-fu Kung ,¶,
Christopher H. K. Cheng and
Ming-liang He , ,¶,¶¶
From the Stanley Ho Center for Emerging Infectious Diseases, School of Public Health and Primary Care,
Institute of Digestive Disease, Department of Medicine and Therapeutics, and
Departments of || Biology and
**Anatomical Cellular Pathology, The Chinese University of Hong Kong , Hong Kong, China,
 Institute of Life and Health Engineering, Jinan University , Guangzhou 510632, China, and
 School of Biomedical Sciences and
¶Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong , Hong Kong, China
Hepatitis B virus (HBV) infection is a global public health problem that plays a crucial role in the pathogenesis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. However, the pathogenesis of HBV infection and the mechanisms of host-virus interactions are still elusive. In this study, two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomics were applied to analyze the host response to HBV using an inducible HBV-producing cell line, HepAD38. Twenty-three proteins were identified as differentially expressed with glucose-regulated protein 78 (GRP78) as one of the most significantly up-regulated proteins induced by HBV replication. This induction was further confirmed in both HepAD38 and HepG2 cells transfected with HBV-producing plasmids by real time RT-PCR and Western blotting as well as in HBV-infected human liver biopsies by immunohistochemistry. Knockdown of GRP78 expression by RNA interference resulted in a significant increase of both intracellular and extracellular HBV virions in the transient HBV-producing HepG2 cells concomitant with enhanced levels of hepatitis B surface antigen and e antigen in the culture medium. Conversely overexpression of GRP78 in HepG2 cells led to HBV suppression concomitant with induction of the positive regulatory circuit of GRP78 and interferon-β1 (IFN-β1). In this connection, the IFN-β1-mediated 2',5'-oligoadenylate synthetase and RNase L signaling pathway was noted to be activated in GRP78-overexpressing HepG2 cells. Moreover GRP78 was significantly down-regulated in the livers of chronic hepatitis B patients after effective anti-HBV treatment (p = 0.019) as compared with their counterpart pretreatment liver biopsies. In conclusion, the present study demonstrates for the first time that GRP78 functions as an endogenous anti-HBV factor via the IFN-β1-2',5'-oligoadenylate synthetase-RNase L pathway in hepatocytes. Induction of hepatic GRP78 may provide a novel therapeutic approach in treating HBV infection.
¶¶ To whom correspondence should be addressed: Stanley Ho Center for Emerging Infectious Diseases, School of Public Health and Primary Care and Li Ka Shing Inst. of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin N. T., Hong Kong, China. Tel.: 852-3763-6096; Fax: 852-2145-8013; E-mail: mlhe{at}cuhk.edu.hk.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2009 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|